Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population

Georgios Angelidakis; Fareed Khawaja; Victor E Mulanovich; Natalie Dailey-Garnes; Ella Ariza-Heredia; Roy F Chemaly

doi:10.1016/j.micinf.2021.104895

Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population

Microbes Infect. 2022 Apr-May;24(3):104895. doi: 10.1016/j.micinf.2021.104895. Epub 2021 Oct 28.

Authors

Georgios Angelidakis¹, Fareed Khawaja¹, Victor E Mulanovich¹, Natalie Dailey-Garnes¹, Ella Ariza-Heredia¹, Roy F Chemaly²

Affiliations

¹ Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: [email protected].

PMID: 34756990
DOI: 10.1016/j.micinf.2021.104895

Abstract

Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.

Keywords: Baloxavir; Combination therapy; HCT; Influenza; Oseltamivir.

MeSH terms

Antiviral Agents / therapeutic use
Dibenzothiepins
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Influenza, Human* / drug therapy
Influenza, Human* / epidemiology
Morpholines
Oseltamivir / therapeutic use
Pyridones
Transplant Recipients
Triazines

Substances

Antiviral Agents
Dibenzothiepins
Morpholines
Pyridones
Triazines
Oseltamivir
baloxavir